The European Medicines Agency’s expert committee looks set to reject Biogen and Eisai’s Alzheimer’s treatment Aduhelm (aducanumab), adding further bad news to the drug’s troubled and controversial US launch.
The companies announced on 17 November that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
